The DOI matches its Crossref record.
The FDA perspective on the development of stereoisomers
Abstract
The current regulatory position of the Food and Drug Administration is discussed with regard to the approval of racemates and pure stereoisomers. Circumstances in which stereochemically sensitive analytical methods are necessay to ensure the safety and efficacy of a drug are described. Regulatory guidelines are interpreted for applications for the approval of a pure enantiomer in which the racemate is marketed, for the approval of eitehr a racemate or a pure enantiomer in which neither is marketed, and for clinical investigations to compare the safety and efficacy of a racemate and its enantiomers. Examples of te basis for such regulation are drawn from historical situations (thalidomide, benoxaprofen) as well as currently marketed drugs (arylproionic acids, disopyramide, indacrinone).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Broadening the Scope of Biocatalysis in Sustainable Organic Synthesis
Sheldon, R. A., & Brady, D. (2019) · ChemSusChem · doi:10.1002/cssc.201900351 · Cited by 306
Contextual Emergence in the Description of Properties
Bishop, R. C., & Atmanspacher, H. (2006) · Foundations of Physics · doi:10.1007/s10701-006-9082-8 · Cited by 183
Chirality in adsorption on solid surfaces
Zaera, F. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00367f · Cited by 172
Metadata
- Authors
- De Camp, W. H.
- Venue
- Chirality
- Publisher
- Wiley
- Published
- 1989-01
- Volume
- 1
- Issue
- 1
- Pages
- 2-6
- ISSN
- 0899-0042 (ISSN-L)
- 1520-636X
- OpenAlex
- W2074243254
- Cited by
- 285
- References
- 0
- FWCI
- 23.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FDA perspective on the development of stereoisomers. https://app.cochat.ai/papers/10.1002/chir.530010103
- The paper
- De Camp, W. H. (1989). The FDA perspective on the development of stereoisomers. Chirality. https://doi.org/10.1002/chir.530010103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.